EAM Investors’s Amphastar Pharmaceuticals AMPH Stock Holding History

EAM Investors’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-68,855	Closed	-$2.4M	–	251
2022 Q2	$2.4M	Sell	68,855 -55,842	-45%	-$1.99M	0.58%	50
2022 Q1	$4.48M	Buy	+124,697	New	+$3.54M	0.83%	7
2019 Q1	–	Sell	-122,250	Closed	-$2.43M	–	255
2018 Q4	$2.43M	Buy	+122,250	New	+$2.41M	0.66%	32
2017 Q1	–	Sell	-173,018	Closed	-$3.19M	–	310
2016 Q4	$3.19M	Sell	173,018 -20,337	-11%	-$396K	0.42%	70
2016 Q3	$3.67M	Sell	193,355 -53,450	-22%	-$970K	0.49%	42
2016 Q2	$3.98M	Buy	+246,805	New	+$3.48M	0.6%	14
2015 Q3	–	Sell	-68,224	Closed	-$1.2M	–	292
2015 Q2	$1.2M	Buy	+68,224	New	+$1.06M	0.14%	275

Other funds holding AMPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM Investors's AMPH Position: Q3 2022 in Review

EAM Investors sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2022, closing a stake of 68,855 shares — an estimated $2.4M sold.

EAM Investors first reported a position in AMPH in Q2 2015 and held it in 7 quarters. The position peaked at $4.48M in Q1 2022. 207 funds tracked by Wall St. Rank hold AMPH as of Q3 2022.

EAM Investors reported no remaining Amphastar Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
EAM Investors sold 68,855 Amphastar Pharmaceuticals shares in Q3 2022, an estimated $2.4M.
EAM Investors first reported a position in Amphastar Pharmaceuticals in Q2 2015 and held it in 7 quarters.
EAM Investors's Amphastar Pharmaceuticals position peaked at $4.48M in Q1 2022.
207 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2022.

Based on EAM Investors's 13F filing for Q3 2022, filed 14 Nov 2022.